Topics › Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics
Pharmaceutical Economics and Policy Sign in to save
Papers per year
Papers 39
Open in paper search →-
Marketing Authorization Applications Made to the European Medicines Agency in 2018–2019: What was the Contribution of Real‐World Evidence?2021 Clinical Pharmacology & Therapeutics article Economics, Econometrics and Finance Pharmaceutical Economics and Policy Open access
Robert Flynn, Kelly Plueschke, Chantal Quinten, Valerie Strassmann, Ruben G. Duijnhoven, María Gordillo‐Marañón, +3 more
133citations -
What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings2020 Cytotherapy article Economics, Econometrics and Finance Pharmaceutical Economics and Policy Open access
Renske M.T. ten Ham, Anke M. Hövels, Jarno Hoekman, Geert Frederix, Hubert G. M. Leufkens, Olaf H. Klungel, +17 more
70citations -
Orphan Medicine Incentives: How to Address the Unmet Needs of Rare Disease Patients by Optimizing the European Orphan Medicinal Product Landscape Guiding Principles and Policy Proposals by the European Expert Group for Orphan Drug Incentives (OD Expert Group)55citations
-
Lessons learned from postmarketing withdrawals of expedited approvals for oncology drug indications2024 The Lancet Oncology article Economics, Econometrics and Finance Pharmaceutical Economics and Policy
Simone N. Koole, Atse H Huisman, Lonneke Timmers, Hans M. Westgeest, Edwin van Breugel, Gabe S. Sonke, +1 more
40citations -
Perspectives and Update on the Global Shortage of Verteporfin (Visudyne®)2024 Ophthalmology and Therapy article Economics, Econometrics and Finance Pharmaceutical Economics and Policy Open access
Marc J. Sirks, Yousif Subhi, Noa Rosenberg, Carla E. M. Hollak, Camiel J. F. Boon, Roselie M.H. Diederen, +6 more
24citations -
Development of medicines for rare diseases and inborn errors of metabolism: Toward novel public–private partnerships2023 Journal of Inherited Metabolic Disease article Economics, Econometrics and Finance Pharmaceutical Economics and Policy Open access
Noa Rosenberg, Nina N. Stolwijk, Sibren van den Berg, Joris J. Heus, Vincent van der Wel, Teun van Gelder, +3 more
11citations -
Real‐World Evidence to Inform Regulatory Decision Making: A Scoping Review2024 Clinical Pharmacology & Therapeutics article Economics, Econometrics and Finance Pharmaceutical Economics and Policy Open access
Marieke S. Jansen, Olaf M. Dekkers, Saskia le Cessie, Lotty Hooft, Helga Gardarsdóttir, Anthonius de Boer, +1 more
10citations -
The IRDiRC Chrysalis Task Force: making rare disease research attractive to companies2023 Therapeutic Advances in Rare Disease article Economics, Econometrics and Finance Pharmaceutical Economics and Policy Open access
Katherine L. Beaverson, Daria Julkowska, Mary Catherine V. Letinturier, Annemieke M Aartsma-Rus, Jennifer Austin, Juan Antonio Bueren, +10 more
7citations -
Real world evidence: Perspectives from a European Society of Cardiology Cardiovascular Round Table with contribution from the European Medicines Agency2023 European Heart Journal - Quality of Care and Clinical Outcomes article Economics, Econometrics and Finance Pharmaceutical Economics and Policy Open access
Piotr Szymański, Franz F. Weidinger, I Lordereau‐Richard, Anders Himmelmänn, Marcello Arca, Charles T. Lee, +9 more
5citations -
Impact of off‐label use regulations on patient care in dermatology – a prospective study of cost‐coverage applications filed by tertiary dermatology clinics throughout Germany2022 Journal of the European Academy of Dermatology and Venereology article Economics, Econometrics and Finance Pharmaceutical Economics and Policy Open access
Ricardo Niklas Werner, Antonia Pennitz, Lisa Eisert, Paul Schmidle, Alexander Zink, Susanne Abraham, +8 more
3citations -
Medication Use and Clinical Outcomes by the Dutch Institute for Clinical Auditing Medicines Program: Quantitative Analysis2022 Journal of Medical Internet Research article Economics, Econometrics and Finance Pharmaceutical Economics and Policy Open access
Rawa Kamaran Ismail, Jesper van Breeschoten, S. van der Flier, Caspar van Loosen, Anna M.G. Pasmooij, Maaike van Dartel, +4 more
3citations -
Paying for precision: funding approaches for N-of-1 trials of individualized gene targeted therapies2026 Orphanet Journal of Rare Diseases article Economics, Econometrics and Finance Pharmaceutical Economics and Policy Open access
Nicole Nolen, Annemieke M Aartsma-Rus, Christine Caneva, Curtis R. Coughlin, Margot A. Cousin, Catherine L. Douthwright, +11 more
3citations -
Disproportional inflation of clinical trial costs: why we should care, and what we should do about it2024 Nature Reviews Drug Discovery article Economics, Econometrics and Finance Pharmaceutical Economics and Policy
Hemme J. Hijma, Ahnjili Zhuparris, Ewoud‐Jan van Hoogdalem, Adam F. Cohen
3citations -
Stakeholders’ experiences with a clinician-led access programme linking evidence generation and reimbursement for precision cancer treatments: the drug access protocol in the Netherlands2026 Acta Oncologica article Economics, Econometrics and Finance Pharmaceutical Economics and Policy Open access
Christine Leopold, Atse H Huisman, Kevin J. G. M. Vlaar, Haiko J. Bloemendal, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani
2citations -
1550P Addressing uncertainties of clinical value and improving access for newly authorised indications through DRUG-Access Protocol (DAP)-like platforms: Joint collection and evaluation of real-world evidence2024 Annals of Oncology article Economics, Econometrics and Finance Pharmaceutical Economics and Policy Open access
Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, A. Huisman, Hans J.L. Timmer, L. Fagereng, Åslaug Helland, Bettina Ryll, +9 more
1citations
Most active Aachen authors
-
Sahar Barjesteh van Waalwijk van Doorn-Khosrovani 3,047 citations overall7 papers
-
Hans A. J. Gelderblom 55,175 citations overall4 papers
-
Annemieke M Aartsma-Rus 20,730 citations overall4 papers
-
Adam F. Cohen 11,184 citations overall3 papers
-
Hans J.L. Timmer 799 citations overall3 papers
-
Atse H Huisman 57 citations overall3 papers
-
Michel W.J.M. Wouters 17,297 citations overall2 papers
-
Pauline Meij 2,285 citations overall2 papers
-
Jesper van Breeschoten 400 citations overall2 papers
-
Ana Hidalgo-Simon 6 citations overall2 papers
-
Rebecca Ultee 3 citations overall2 papers
-
Glenn van Veldhoven 3 citations overall2 papers
-
Egbert Frederik Smit 62,735 citations overall1 paper
-
Olaf M. Dekkers 38,869 citations overall1 paper
-
Saskia le Cessie 32,552 citations overall1 paper